The CAR T Cell Therapy market is projected to reach USD 7.2 Billion by 2032 at 14.5% CAGR during the forecast period 2024-2032. Chimeric Antigen Receptor (CAR)-T is a novel treatment that includes reengineering of the WBC’s of the patient to help in fighting the malignant cells by identifying them.
In 2024, the FDA approved a groundbreaking immunotherapy created by Iovance Biotherapeutics, bringing the T-cell therapy treatment class—which has revolutionized the treatment of certain blood cancers—to the solid tumor sector. The medication, known as Amtagvi, also known as lifileucel, is the first tailored tumor-infiltrating lymphocyte (TIL) therapy available on the market. For patients with metastatic melanoma who have previously had treatment with a PD-1 inhibitor—and a BRAF inhibitor if the tumor possesses a BRAF V600 mutation—the FDA on Friday awarded it an accelerated approval.
Kyverna Therapeutics, Inc. (Kyverna) is a patient-centered clinical-stage biopharmaceutical company that specializes in developing cell therapies for patients with autoimmune diseases. The company announced in 2024 that the FDA in the United States had cleared its application for an investigational new drug (IND). KYV-101, a completely human CD19 chimeric antigen receptor (CAR) T-cell product candidate, is intended to be used as an MS therapy.
Max Healthcare and ImmunoACT collaborate to introduce CAR-T cell treatment in 2023.Referred to as a "living drug," this treatment offers long-lasting advantages and is suggested for individuals unable to receive a stem cell transplant or experiencing a relapse following a transplant. With an average of two weeks of in-patient care, this needs a brief, single-infusion treatment, which is less intrusive than conventional therapies and improves the quality of life for many patients.
COVID 19 Analysis
Owing to the advanced degree to which the global coronavirus pandemic is unfolding and the continuous variants and waves that have disrupted the lives of people across the globe, the industries, and market players are equally suffering the wrath. So much so, that some of the business players have given up and they are shutting their manufacturing and production units. Also, the imposed lockdown has not proved to be of any benefit as people are working from home which is disrupting both their personal and professional life, thus, resulting in an increased degree of unavailability of a skilled workforce that is further, hampering the ability to meet the demand quantum as a result of inefficient production. Also, the raw material available is no or very little quantity that is hampering the quality of products and it has become nearly impossible for the businesses to function amid a series of restrictions and cross-border difficulties.
Hence, the need of the hour is for the public sector to intervene and the governments of the global locations to enhance the funds that will help in the market’s revival. Also, it is important to understand that the population is increasing and the demands of people are different. The key market players should enhance their production ability and take it to the international market to launch a variety of products. Also, mergers and acquisitions are an important and innovative way to help the target audience choose from a variety of products and change their lifestyle preferences accordingly.
Drivers
The CAR-T cell therapy market companies are expected to thrive at an excellent rate during the ongoing forecast period of 2021-2027. The overall industry has a very dynamic approach and the key players belonging to the market are gaining access in the major CAR-T cell therapy market size. The companies are securing the treatment centers that will help in increasing patients owing to the development of a series of medical service demands.
Restraints
There have various growth restraints that emerge as major issues for the market while on its path of growth during the forecast period that ends in 2032. One of the major restraints that the market players tend to face is the lack of demand for treatment. The target population is too rigid and understands the native methods of treatment only. Also, the associated cost for treatment is very high that does not sit well with the people as they belong to different income groups and spending capacities. If the cost and prices are not reduced, the global CAR-T cell therapy market trends and operations are likely to pose major restraints for the market and bar the market from growing as per the predictions laid by the industry leaders and market experts during the forecast period of 2021-2032.
Technology Analysis
The rising rate of people being diagnosed with various types of cancer is one of the major reasons that lead to the death of the global population. Hence, the need of the hour is for the companies to evolve the conventional and cytotoxic immunotherapies that are available on the global market scale. The tumors are believed to have complex behaviors and the degree of involvement of a variety of cellular and genetic factors in metastasis and tumorigenesis is pushing the companies to divert their trends in the development of new treatment trends so that the main focus lays on tumors at both the stated levels.
Study Objectives
The CAR-T cell therapy market report shows that the market has been segmented based on the following:
The global CAR-T cell therapy market by targeted antigen includes BCMA that is B-Cell maturation antigen, CD19/CD22, and others like PSCA, Lewis Y, ROR1, NKR-2, and MUC16 amongst others.
The application market segment of the CAR-T cell therapy includes Diffuse Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia and Other.
Based on the division of the target audience, types of equipment, and resources, the market of CAR-T cell therapy has been divided into 4 major regions namely North America, Europe, the APAC region, and the rest of the world.
The CAR-T cell gene therapy market analysis shows that the North American region shows signs of excellent growth during the period and is expected to grow at a global CAGR of 36.4%. Similarly, the changing trends in the European market and the increased use of proper technology will help the CAR-T cell therapy market grow at a significant rate. The recommended approvals of Yescarta and Kymriah by the European Medicine Agencies (EMA), are showing signs of positive attributes that will help the market boost its overall growth during the forecast period that ends in 2028.
Competitive Landscape
The rising degree of competition in the global market scenario of CAR-T cell therapy is the result of recent developments of CAR-T cell therapy companies. They are as follows:
Recent Developments
Report Overview
The curated reports aim to have a deep and helpful discussion of the global manufacturing of the CAR-T cell therapy in terms of the market trends and dynamics that will lead the market towards splendid growth during the ongoing forecast period that ends in 2032. The CAR-T cell therapy market report aims to help the market investors gain qualitative market insights related to the performance of the market segments and the growth strategies taken by the market players in various regions during the period that will help both the companies and the domestic regions to grow on the international market scale. Also, the report is a clear depiction of the rising competition amongst the key market players and the aim is to consider the recent developments undertaken during the ongoing forecast period that ends in 2032.
| Report Attribute/Metric | Details |
| Market Size | USD 7.2 Billion |
| CAGR | 14.5% |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Target Antigen, Application and Region |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Pfizer (US), Kite Pharma (US), Novartis (Switzerland), Cellectis (Switzerland) and Juno Therapeutics (US) |
| Key Market Opportunities | Increase in the setups of research & development centers and the inclination of top companies toward the developing countries boost |
| Key Market Drivers | prevalence of cancers is increasing the demand for effective treatmentThe growth of the obese population |
CAR T Cell Therapy Market Highlights:
Frequently Asked Questions (FAQ) :
The Market is expected to rise to a valuation of USD 7.2 Billion by 2032.
The global market is expected to exhibit a strong 14.5% CAGR over the forecast period.
The growing prevalence of cancer and the growing support for the development of effective therapies against cancer is the major driver for the market.
The U.S. holds an overwhelming majority in the global market and is likely to remain the dominant regional market over the forecast period.
Leading players in the market include Novartis, Pfizer, Juno Therapeutics, Kite Pharma, Autolus Therapeutics plc, CARsgen Therapeutics, Cellectis, and Sorrento Therapeutics, among others.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
